Delving into the Latest Updates on Sichuan Huiyu Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Biological products

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	21
Endocrinology and Metabolic Disease	4

Top 5 Drug Type	Count

Small molecule drug	11
Biological products	5
Chemical drugs	5
Antibody drug conjugate (ADC)	2
Monoclonal antibody	2

Top 5 Target	Count

CDCP1 x Tubulin	2
PD-1(Programmed cell death protein 1)	1
SOS1(Son of sevenless homolog 1)	1
KRAS G12D(GTPase KRas G12D)	1
IL-15 x IL-15Rα x PD-1 x PDL1 x TIGIT	1

主要目的：评估前列腺癌患者使用受试制剂（四川汇宇制药股份有限公司生产的醋酸戈舍瑞林缓释植入剂，规格：3.6 mg/支）与参比制剂（TerSera Therapeutics LLC 持证的醋酸戈舍瑞林缓释植入剂，规格：3.6 mg/支）的吸收速度和吸收程度的差异，并评价两制剂在前列腺癌患者中生物等效性。次要目的：评估受试制剂T与参比制剂R中受试者的安全性。

[Translation]

Primary objective: To evaluate the difference in absorption rate and extent of the test formulation (goserelin acetate sustained-release implant produced by Sichuan Huiyu Pharmaceutical Co., Ltd., specification: 3.6 mg/vial) and the reference formulation (goserelin acetate sustained-release implant certified by TerSera Therapeutics LLC, specification: 3.6 mg/vial) in patients with prostate cancer, and to evaluate the bioequivalence of the two formulations in patients with prostate cancer. Secondary objective: To evaluate the safety of subjects in the test formulation T and the reference formulation R.

Start Date02 Jul 2025

Sponsor / Collaborator

Sichuan Huiyu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Sichuan Huiyu Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sichuan Huiyu Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Sichuan Huiyu Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sichuan Huiyu Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

17

Preclinical

Phase 1

1

5

Phase 2

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HY-07121 ( IL-15 x IL-15Rα x PD-1 x PDL1 x TIGIT )	Advanced Malignant Solid Neoplasm More	Phase 1/2
HY0001a ( CDCP1 x Tubulin )	Advanced Malignant Solid Neoplasm More	Phase 1/2
HYP-2090PTSA ( Class I PI3K x KRAS G12C )	Advanced Malignant Solid Neoplasm More	Phase 1/2
HYP-6589 ( SOS1 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
HY-2003	Localized obesity More	Phase 1